1. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells.
- Author
-
Leroux ME, Auzenne E, Evans R, Hail N Jr, Spohn W, Ghosh SC, Farquhar D, McDonnell T, and Klostergaard J
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma enzymology, Cell Line, Tumor, Cell Survival drug effects, Down-Regulation, Humans, Male, Prostatic Neoplasms drug therapy, Prostatic Neoplasms enzymology, Sphingosine pharmacology, Adenocarcinoma pathology, Apoptosis drug effects, Ceramides pharmacology, Enzyme Inhibitors pharmacology, Phosphotransferases (Alcohol Group Acceptor) antagonists & inhibitors, Prostatic Neoplasms pathology, Proto-Oncogene Proteins c-bcl-2 metabolism, Sphingosine analogs & derivatives, Thiazoles pharmacology
- Abstract
Background: Elevated BCL-2 is one mechanism of therapeutic resistance in prostate cancer (PC), and new approaches are needed to overcome such resistance., Methods: We evaluated the effects of BCL-2 over-expression in human prostatic adenocarcinoma cells on their susceptibility to sphingolipids (SLs) and to the sphingosine kinase (SpK) inhibitor, SKI II., Results: In survival assays, no significant differences were observed in the responses to sphingosine or ceramide among parental PC-3 cells lacking detectable BCL-2 and BCL-2 over-expressing PC-3 transfectants; similarly, the responses to dimethyl-sphingosine (DMSP) of parental LNCaP cells and a BCL-2 over-expressing LNCaP transfectant were equivalent. SKI II induced protracted, BCL-2-independent survival loss in both PC-3 and LNCaP parental/transfectant pairs; in contrast, DMSP induced rapid cell shrinkage, caspase activation and caspase-dependent DNA fragmentation. DMSP-induced DNA fragmentation and loss of mitochondrial membrane potential were equivalent in BCL-2 transfectants and parental PC-3 cells and were not associated with BCL-2 downregulation. DMSP-mediated cytotoxicity was not associated with the enhanced production of reactive oxygen intermediates. SL analyses of parental and transfectant PC-3 cells did not reveal increased levels of sphingosine-1-phosphate in the BCL-2 transfectants; further, there only a modest early shift, corresponding to apoptotic onset, in pro- versus anti-apoptotic SLs in response to DMSP treatment., Conclusions: Thus, in contrast to the inhibitory effects of BCL-2 on apoptosis induced by various agents in tumor cells, SKI II and selected pro-apoptotic SLs appear atypical in their independence from such inhibition, and may have merits as new candidates for treatment of AI PC.
- Published
- 2007
- Full Text
- View/download PDF